Dias nummer 1

Download Report

Transcript Dias nummer 1

Quinolones: mechanisms of resistance

Niels Frimodt Møller

National Center of Antimicrobials and Infection Control Statens Serum Institut Copenhagen, Denmark

Quinolone mechanisms of resistance 1) Change in receptor

Mutations in genes for gyrases/topoisomerases

2)

Change in penetration

Efflux-mechanisms: Proton-pumps with active transport of quinolone out of cell 3)

Enzymatic degradation

Always (almost) chromosomal (plasmid carried transfer found in Klebsiella, mechanism?)

Gram negativ bakterie kinolonresistensmekanismer.

DNA + gyrasekomplex Porer Effluxpumper

DNA

Structure of the Topo I/DNA complex

. During replication, the unwinding of DNA may cause the formation of tangling structures, such as supercoils or catenanes . The major role of topoisomerases is to prevent DNA tangling.

The structure of supercoils.

(a)

Positive supercoils - the front segment of a DNA molecule cross over the back segment from left to right.

(b)

Negative supercoils.

bacteria during DNA replication.

(c)

The positive supercoil in

There are two types of topoisomerases

:

type I

produces transient

single-strand

breaks in DNA:

The topo I

of both prokaryotes and eukaryotes and

types II

produces transient

double-strand

breaks: The eukaryotic topo II,

bacterial gyrase

, and

bacterial topo IV

belong to the type II The

gyrase

has two functions: (1) to remove the positive supercoils during DNA replication, (2) to introduce negative supercoils (one supercoil for 15-20 turns of the DNA helix) so that the DNA molecule can be packed into the cell. During replication, these negative supercoils are removed by topo I.

Malfunction in topoiomerases causes cell death.

The function of topo II: (a)

To remove supercoils. This involves a double-strand break (indicated by a short line), allowing the tangled segment to pass through. The break is then resealed.

(b)

To remove catenanes. The topo II makes a double-strand break in one DNA molecule (the blue one), allowing the other molecule to pass through. The break is then resealed.

Quinolone resistance mechanism

Topoiso merase II Gyrase

(catalyses ATP-dep. negative supercoiling of DNA-molecule)

Topo IV

(Effect on chromo somal segregation) Subunit A (

gyrA

) Subunit B (

gyrB

) Subunit C (

parC

) Subunit E (parE)

Quinolone resistance mechanism

Topoiso merase II

Gyrase

(catalyses ATP-dep. negative supercoiling of DNA-molecule)

Topo IV

(Effect on chromo somal segregation)

Subunit A (gyrA ) Subunit B (gyrB) Subunit C (parC) Subunit E (parE) Mutations in gyrA QRDR resistance in Gram-negatives Mutations in parC QRDR resistance in Gram-positives

Gram negativ bakterie kinolonresistensmekanismer.

DNA + gyrasekomplex Porer Effluxpumper

Accumulation of moxifloxacin in

P. aeruginosa

+/- CCCP (efflux inhibitor)

Ng mox./mg dry cell

90 80 70 60 50 40 30 20 10 0 5 10 15 20 alone + CCCP

Minutes

Accumulation of ciprofloxacin and lomefloxacin in fluoroquinolone-resistant strains of Escherichia coli

XIA Peiyuan et al. Chin Med J 2002; 115:31-5.

Accumulation of LMLX in E. coli strains. Each curve indicates the accumulated concentration of LMLX in one strain at diffe rent time point.JF701 and JF703: control strains ; Ecs: susceptible strain. R 2 and R256: the in vitro selected resistant strains;

R5 and R6: the clinical res istant strains.

Involvement of Topoisomerase IV and Gyrase as Ciprofloxacin targets in

S. pneumoniae

Strain

D5 B10 D11 E4

Mutations in QRDR of: ParC GyrA GyrB ParE Cipro MIC

1 Ser-79  Phe Ser-79  Phe Arg-95  Cys Glu-87 > Lys 4 64 4 Pan et al. Antimicrob Ag Chemother 1996, 40: 2321-6

Quinolone resistance types in

E. coli

Strain Mutation in gyrA Mutation in parC Redu ced accum.

ATCC25922 WT-4 MI WT-3 WT-3-M4 MII MIII S83 S83+D87 S83+D87 S83 S83+D87 S80I S80I S80I + + Cipro MIC 0.008

0.008

0.5

1 64 2 256 Moxiflox MIC 0.03

0.25

1 2 32 4 128 Schedletzky et al. JAC, 1999, 43 suppl.B: 31-7

Effect of fluoroquinolone concentration on the recovery of single-step, resistant mutants.

Moxifloxacin

(open circles) or

levofloxacin

(solid circles). Unlabeled arrows indicate MIC 99 . The triangle indicates no colony recove red at that drug concentration and bac terial load. The dashed line indicates one colony recovered per 10 10 cells tested. Three strains were tested: wild-type strain ATCC 49619 (

A

); strain KD2138, a ParC (Ser-79 to Tyr) variant (

B

); and strain KD2139, a GyrA (Ser-81 to Phe) variant (

C

).

Two double mutants were recovered from each point indicated by an arrow .

Li et al. Antimicrob Ag Chemother 2002, 46: 522-524.

Changes in the susceptibility of S. aureus 201 during and after 3-day treatments with four fluoroquinolones at different AUC 24 /MIC ratios.

Firsov et al. Antimicrob Ag Chemother 2003, 47: 1604-1613

Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae

Blondeau et al., Antimicrob Ag Chemother 2001, 45: 433-438 Relationship of pharmacokinetics and MPC Fluoroquinolone Moxifloxacin Gatifloxacin Trovafloxacin Grepafloxacin Levofloxacin MPC pr90 (µg/ml) 2 4 4 8 8 Dose (mg) 400 400 200 600 500

C

max (µg/ml) 4.5

4.2

3.1

<2.7

5.7

t 1/2 (h) 12 8 12 14 8

Thomas JK, et al. Antimicrob Agents Chemother 1998; 42: 521-7.

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy.

• Five different regimes in ICU could be avaluated for resistance developments in different bacterial species (total of 128 patogenes in 107 ptt.).

– cirofloxacin alone – ciprofloxacin + piperacillin – ceftazidime alone – ceftazidime +tobramycin – cefmenoxime alone

The overall predictor for development of resistance was AUC/MIC < 100.

• Combination therapy resulted in lower rates of resistance.

Thomas JK et al. Antimicrob Ag Chemother 1998; 42: 521-7.

AUC/MIC > 100

• Resistance developed in  lactamase-type-I Gram-neg. rods even when AUC/MIC > 100 after  -lactam monotherapy.

• Median time to resistance: 6 days if AUC/MIC < 100.

AUC/MIC < 100

Quinolone resistance: Summary

1. Mutations in genes for topoisomerases (gyr, par): MIC increases with no. of mutations; rate ~ 1 in 10-7 2. Changes in efflux mechanisms: Pumps out drug; NB: inhibitors; Can be first step in development of resistance 3. Both 1 and 2 can be present in same strain – leads to high MIC ´s

Majority of R-genes chromosomal – plasmid transported gene reported